Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Alfayez, Mansour  [Clear All Filters]
2024
Alyamany R, Alnughmush A, Almutlaq M, Alyamany M, Alfayez M. Azacitidine induced lung injury: report and contemporary discussion on diagnosis and management. Front Oncol. 2024;14:1345492.
2023
Kotb A, Alzahrani H, AlAhmari A, AlHayli S, Shaheen M, Chaudhri N, Alsharif F, Hanbali A, Alfraih F, AlShaibani AF, et al. Incidence and risk factors for secondary graft failure in uniformly treated patients with severe aplastic anemia receiving fludarabine and cyclophosphamide for conditioning and matched sibling bone marrow graft as stem cell source. Cytotherapy. 2023.
Tailor IK, Alshehry NF, Zaidi SZ, Marei MA, Motabi IH, Alfayez M, Altaf SY. Outcome of Myeloma Patients with COVID-19 on Active Lenalidomide-Based Therapy: Does Lenalidomide Protect From Severe COVID-19?. Hematol Oncol Stem Cell Ther. 2023;16(1):88-90.
2021
Alotaibi H, Aljurf M, de Latour R, Alfayez M, Bacigalupo A, Fakih REl, Schrezenmeier H, Ahmed SOsman, Gluckman E, Iqbal S, et al. Upfront Alternative Donor Transplant Versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack Fully HLA Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies. on Behalf of the Severe Aplastic Anemia W. Transplant Cell Ther. 2021.
2020
Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, et al. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer. 2020.
2019
Galloway-Peña JR, Shi Y, Peterson CB, Sahasrabhojane P, Gopalakrishnan V, Brumlow CE, Daver NG, Alfayez M, Boddu PC, Khan MAbdul Wadu, et al. Gut Microbiome Signatures are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia. Clin Infect Dis. 2019.